Canaccord analyst Richard Close lowered the firm’s price target on Teladoc to $36 from $40 and keeps a Buy rating on the shares. The analyst said they reported solid Q4 results but formal 2023 revenue guidance came in well below estimates however, Teladoc is still in an enviable position with its relative financial stability, broad scope of services, and massive footprint.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TDOC:
- Teladoc Health to Participate in Upcoming Investor Conference
- Teladoc’s BetterHelp to pay $7.8M in settlement with FTC
- Teladoc price target lowered to $27 from $31 at Deutsche Bank
- SVB Securities upgrades Teladoc to Outperform as bear thesis reflected in shares
- Teladoc upgraded to Outperform from Market Perform at SVB Securities
